Digoxin effects in infants with single‑ventricle heart failure
Official title: Digoxin Pharmacodynamics in Infants with Heart Failure due to Single Ventricle Congenital Heart Disease
Funded at Duke University · NIH-11045660 · Data updated 2026-11-12
This project looks at how the heart drug digoxin behaves and affects newborns and infants who have heart failure from single‑ventricle congenital heart disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | April 1, 2022 |
| Project end | February 28, 2027 |
| Funding year | 2026 |
| Award (this year) | $661,643 |
| NIH project number | 5R01HD106588-04 |
| Project ID | NIH-11045660 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are newborns and infants with single‑ventricle congenital heart disease who have heart failure and who are receiving or may receive digoxin as part of their care.
✕Less likely to help
Children without single‑ventricle heart disease, older children or adults, or patients who will not receive digoxin are unlikely to benefit directly from this work.
What this research studies
If your baby has single‑ventricle heart disease and heart failure, this work would measure digoxin levels in the blood, check kidney function, and watch how the heart responds while on the medicine. Doctors will collect small blood samples, clinical measurements, and chart information during routine care and use those data to map how dose, growth, and illness change drug exposure and effect. The team will use those measurements to build models that predict safe and effective dosing for different ages and clinical situations. The goal is to reduce guessing about dosing and to help clinicians give the right amount of digoxin to infants with this condition.
Why it matters
Potential benefit: If successful, this could lead to safer, more accurate digoxin dosing and potentially fewer deaths or transplants among infants with single‑ventricle heart failure.
How similar studies have gone: Retrospective studies suggested digoxin may improve survival in infants with single‑ventricle disease, but prospective pharmacokinetic/pharmacodynamic studies in this population are new.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Hornik, Christoph — Duke University
- Study coordinator: Hornik, Christoph
Related research
Other NIH-funded projects on the same topics.
-
Investigating digoxin's effects on infants with heart failure from congenital heart disease
This study is looking at how the heart medicine digoxin works in babies with heart failure caused by a specific heart condition, hoping to find better ways to help these little ones feel better and live healthier lives.
-
Lipid damage and mitochondria: new ways to protect the Fontan heart
A Stanford-led study aims to find new targets and biomarkers to preserve heart function in children with Fontan circulation by looking at how oxidative stress damages heart cell powerhouses and affects blood vessels.
-
Investigating how mitochondrial injury affects blood vessel function in children with congenital heart disease.
This study is looking at how heart failure affects children who have had a special heart surgery called the Fontan operation, with the goal of finding new ways to spot heart problems early and improve treatments for them.
-
Understanding the genetic and social factors affecting heart failure in people with congenital heart disease
This study is looking at how genes and social factors affect heart failure and survival in people with congenital heart disease, and it's designed to help improve care for those at higher risk.
-
Multimodal AI to improve genetic diagnosis of congenital heart disease
A new AI tool uses multiple types of patient data to help doctors find genetic causes of congenital heart disease more accurately.
-
Multimodal AI to improve genetic diagnosis of congenital heart disease
A big AI project will help doctors and families by better identifying genetic causes of congenital heart defects using imaging, medical data, and genome information.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.